eIF1AY inhibitors represent a class of compounds that specifically target and inhibit the activity of the eukaryotic translation initiation factor 1A (eIF1A), which is essential in the initiation phase of protein synthesis. eIF1A plays a crucial role in stabilizing the binding of the initiator tRNA to the small ribosomal subunit and promoting the proper scanning of the messenger RNA (mRNA) for the start codon. By inhibiting eIF1A, these compounds disrupt the normal initiation process, leading to a decrease in overall protein synthesis. This inhibition can have significant effects on cellular processes, as protein synthesis is fundamental to cell growth, division, and response to environmental stimuli.
The mechanism of action of eIF1AY inhibitors involves binding to specific sites on the eIF1A protein, thereby preventing its interaction with the ribosomal subunits and other initiation factors. This binding can induce conformational changes in eIF1A, rendering it incapable of performing its function in the initiation complex. The development and study of eIF1AY inhibitors have provided valuable insights into the molecular dynamics of translation initiation and the regulatory mechanisms controlling protein synthesis. These compounds have also been used as tools in research to dissect the roles of eIF1A in various cellular pathways and to understand the broader implications of translational control in cellular physiology. The study of eIF1AY inhibitors continues to be a dynamic field, contributing to our understanding of the intricate processes that govern gene expression at the translational level.
SEE ALSO...
Items 11 to 16 of 16 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
DNA damage from Doxorubicin may cause the cell to prioritize DNA repair over regular functions, potentially suppressing RNAi machinery and decreasing eIF2C2 levels. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin′s inhibition of topoisomerase I can cause DNA damage, which might lead to a reduced focus on RNAi processes and subsequent lower eIF2C2 expression. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
By inhibiting Hsp90, Geldanamycin may destabilize proteins associated with RNAi, which could include a decrease in eIF2C2 stability or synthesis. | ||||||
Silvestrol | 697235-38-4 | sc-507504 | 1 mg | $920.00 | ||
A natural compound isolated from the plant Aglaia foveolata, known for its potent inhibition of EIF4AI. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $275.00 $474.00 $1639.00 $2497.00 $5344.00 | 4 | |
Another natural compound found in several plants, such as the Aglaia genus, with strong EIF4AI inhibitory activity. | ||||||
4E1RCat | 328998-25-0 | sc-361085 sc-361085A | 10 mg 50 mg | $193.00 $813.00 | ||
A synthetic EIF4AI inhibitor designed to disrupt the eIF4F complex, thereby inhibiting cap-dependent translation. | ||||||